IP Library Granted Patent US 7,811,822
Granted Patent B2
US 7,811,822 · App. 11/880,213 · Granted Oct 12, 2010

Modulation of neural stem cells and neural progenitor cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,811,822
App. No.
11/880,213
Granted
Oct 12, 2010
Kind
B2
Abstract

The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells via S1P or LPA signaling. These methods are useful for reducing at least one symptom of the disorder.

Claims (9)

1. A method of modulating the activity of an S1P, LPA, EDG receptor or a combination thereof, on an adult neural stem cell (NSC) comprising the step of exposing the cell expressing the receptor to a modulator agent selected from the group consisting of S1P, LPA or EDG receptor agonist, wherein the exposure induces increased NSC proliferation compared to untreated cells, and wherein the NSC is derived from adult brain, neural cell culture or a neurosphere.

2. The method of claim 1 wherein the EDG receptor is selected from the group consisting of EDG1, EDG2, EDG3, EDG4, EDG5 and EDG8.

3. A method for stimulating mammalian adult NSC proliferation comprising the step of contacting a cell population comprising mammalian adult NSC to an agent selected from the group consisting of an S1P, LPA or EDG receptor agonist to form a treated NSC, wherein the treated NSC cell shows increased proliferation compared to untreated cells, and wherein the NSC is derived from lateral ventricle wall of a mammalian brain.

4. The method of claim 3 wherein the EDG receptor is selected from the group consisting of EDG1, EDG2, EDG3, EDG4, EDG5 and EDG8.

5. A method for stimulating primary adult mammalian NSC to proliferate to form neurospheres comprising contacting the cell with an agent selected from the group consisting of an S1P, LPA or EDG receptor agonist to produce a proliferating NSC.

6. The method of claim 5 wherein the EDG receptor is selected from the group consisting of EDG1, EDG2, EDG3, EDG4, EDG5 and EDG8.

7. A method of enhancing neural stem cell proliferation in a patient having a central nervous system disorder comprising the step of infusing an S1P, LPA or EDG receptor agonist thereof into the patient, wherein neural stem cells show increased proliferation compared to untreated cells.

8. The method of claim 7 wherein the EDG receptor is selected from the group consisting of EDG1, EDG2, EDG3, EDG4, EDG5 and EDG8.

9. The method of claim 7 wherein the infusion is selected from the group consisting of intraventricular, intravenous, sublingual, subcutaneous and intraarterial infusion.

Assignments (2)
CHANGE OF NAME Recorded Jul 17, 2014
From: NEURONOVA AB
To: NEWRON SWEDEN AB
Reel/Frame 033358/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2010
From: LINDQUIST, PER; MERCER, ALEX; RONNHOLM, HARRIET; WIKSTROM, LILIAN
To: NEURONOVA AB
Reel/Frame 024916/0694 →